OS in ELN favorable-risk patients. (A) HMA + VEN demonstrated improved OS in patients age >65 years compared with both HMA and IC (median OS, NR vs 0.5 vs 1.0 years; P < .001 and .005, respectively). (B) HMA + VEN continued to be associated with a significant improvement in OS in ELN favorable-risk patients age >60 years.